---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-063712"
form_type: "8-K"
ticker: "SKIN"
cik: "0001818093"
company_name: "SkinHealth Systems Inc."
filed_at: "2026-09-28T20:05:22+00:00"
generated_at: "2026-10-12T13:34:54.660958+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# SkinHealth stockholders approve reverse split of 1-for-5 to 1-for-20 at September 22 special meeting

## Summary
- Proposal 1 passed with 114,398,602 votes for, 1,406,150 against and 88,570 abstentions; exact split ratio left to the board's sole discretion within the 1-for-5 to 1-for-20 range.
- Proposal 2, allowing adjournment for further proxy solicitation, passed 114,344,814 for to 1,450,597 against, with 97,911 abstentions.
- 130,140,763 Class A shares outstanding as of the August 3, 2026 record date; 115,893,322 shares (89.05%) present virtually or by proxy, establishing a quorum.
- No broker non-votes were recorded on either proposal; matters were described in the Definitive Proxy Statement on Schedule 14A filed August 12, 2026.
- Filing signed by Michael Monahan, Chief Financial and Operating Officer, dated September 28, 2026.

## SEC filing metadata
- accession: 0001628280-26-063712
- form_type: 8-K
- ticker: SKIN
- cik: 0001818093
- company_name: SkinHealth Systems Inc.
- filed_at: 2026-09-28T20:05:22+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818093/000162828026063712/0001628280-26-063712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818093/000162828026063712/skin-20260922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-063712
- JSON: https://secwatch.observer/filing/0001628280-26-063712.json
- Plain text: https://secwatch.observer/filing/0001628280-26-063712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.